Takara Bio expands custom enzyme manufacturing capability in Sweden
Takara Bio Europe has expanded its Gothenburg facility with a new custom manufacturing laboratory, significantly boosting its capacity to produce molecular biology reagents for the EMEA region. The facility, which became operational on 1 October 2024, is capable of manufacturing up to 600,000 reactions weekly, addressing the growing demands of academic research institutions, diagnostic laboratories, and biotechnology companies.
Localised manufacturing to reduce delivery times
The Swedish facility, previously known for its Cellartis stem cell products and reagents, has broadened its manufacturing capabilities to include customised molecular biology products, with a particular focus on PCR and qPCR enzymes. This strategic expansion aims to strengthen the company’s position in providing specialised molecular biology solutions whilst reducing delivery times and environmental impact through localised production.
“This expansion strengthens our ability to deliver custom solutions with increased flexibility and faster turnaround times,” said Kristina Runeberg, Site Head, Takara Bio Europe – Swedish Filial. “By producing closer to our customers, we can better meet their needs while reducing our carbon footprint.”
Technical expertise and product portfolio
The expanded facility offers real-time access to technical expertise, enabling researchers to optimise their molecular biology workflows more efficiently. The site’s comprehensive product range includes established molecular biology tools such as SMART cDNA synthesis kits for next-generation sequencing (NGS), high-performance PCR and qPCR reagents, and the company’s proprietary enzyme lines including Takara Ex Taq, Takara LA Taq, Titanium, and Advantage enzymes.
The facility’s enhanced capabilities will support a broad spectrum of applications crucial to modern biomedical research, including:
• NGS library preparation and analysis
• Gene discovery and functional studies
• Genetic analysis and manipulation
• Protein expression and purification
• CRISPR-based gene editing
• Stem cell research
• Plant and food science investigations
The expansion represents a significant investment in the European life sciences infrastructure, positioning Takara Bio to better serve the growing demands of the molecular biology research community while advancing their commitment to sustainability through reduced transportation requirements and associated carbon emissions.
The facility’s increased capacity for custom manufacturing, combined with its ability to provide rapid technical support and reduced delivery times, is expected to accelerate research timelines for European institutions engaged in translational and clinical research programmes.
